Thursday, February 27, 2014
AstraZeneca plc has a burgeoning
network of public-private partnerships, but until now the pharma has lacked a
presence in the San Francisco Bay Area, one of the U.S.'s major hubs of life
sciences innovation. AstraZeneca now has remedied that, as its MedImmune LLC biologics unit is piggybacking
onto an NIH-sponsored initiative to support
translational research at the University of California, San Francisco.
Over the last three years, AstraZeneca has built an extensive
network of academic collaborations geared toward filling the pharma's early
pipeline. In 2013, AstraZeneca led the industry in forming public-private
partnerships (PPPs), entering at least 14
disclosed PPPs with a variety of academic institutions worldwide.1
L. SciBX 7(8); doi:10.1038/scibx.2014.216 Published online Feb. 27, 2014
1. Edelson, S. & Lou,
K.-J. SciBX 7(7); doi:10.1038/scibx.2014.188
AND INSTITUTIONS MENTIONED
(LSE:AZN; NYSE:AZN), London, U.K.
The Johns Hopkins University, Baltimore, Md.
National Institutes of Health, Bethesda, Md.
Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J.
University of California, San Francisco, Calif.
University of Maryland, Baltimore, Md.